Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ATP may help reduce ribociclib-induced skin damage in rats by mitigating biochemical changes associated with oxidative stress.

In this study, two patients with alopecia universalis continued using tofacitinib during active COVID-19 infection and showed no worsening of their illness, despite potential concerns about immunosuppression.

This case study reports that tofacitinib led to remission of psoriasis but did not improve alopecia universalis in one patient, suggesting varied responses in treating such conditions.

Baricitinib helps with early hair regrowth in people with alopecia areata.

This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.

This case report describes how personalized treatment based on Encyclopedic Tumor Analysis successfully led to durable regression in a woman with advanced pilomatrical carcinoma, unresponsive to standard care.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

In this study, YK11 was found to promote osteoblast cell proliferation and differentiation through activation of non-genomic signaling pathways in mouse osteoblast cells.

This study found that dermatologic adverse events are common in children taking MEK inhibitors, with selumetinib patients experiencing less severe reactions and a lower risk of dosage adjustments. Age was noted as a factor in the likelihood of specific skin reactions.

In this real-world study, JAK inhibitors like abrocitinib and tofacitinib led to substantial hair regrowth in 61% of alopecia areata patients over a median of 16 months, with 75% of non-responders achieving regrowth after switching medications; however, two serious adverse events were noted.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

CRISPR/Cas9 and prime editing can potentially fix skin disorder genes safely and effectively.

This study found that targeting RARβ and RXRA with CANA, in combination with MPA, could help overcome progestin resistance by restoring BAX levels and downregulating CRABP2, suggesting a novel strategy for improving clinical efficacy in this context.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

This study observed that among UK alopecia areata patients seeking JAK inhibitor treatments before public funding, many sourced medication from abroad due to high costs, with variable response rates and significant reliance on social media for information on accessing treatments.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

This article reviews the use of sorafenib, a multikinase inhibitor, for treating certain carcinomas, noting that cutaneous toxicity during treatment may indicate successful antitumor activity; however, it reports no new clinical results.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.

This study observed that 71% of chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors experienced adverse cutaneous reactions, which were generally less severe than those caused by imatinib.

This study found that a single dose of TRP significantly reduced the number of UV-B-induced actinic keratosis lesions in a mouse model and was associated with improved skin histology and minimal side effects.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

In this randomized controlled trial, researchers found that after six months of treatment, oral baricitinib was significantly more effective than methotrexate for improving hair regrowth in patients with severe alopecia areata, as measured by the Severity of Alopecia Tool score.

Repetin is a protein involved in skin and hair development, binding calcium and compensating for other proteins when needed.

This study found that selective androgen receptor modulators (SARMs) significantly inhibited tumor growth and metastasis-promoting factors in AR-positive triple-negative breast cancer models.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.

This case report describes the management of PRIDE complex, a skin and hair condition associated with EGFR inhibitor treatment like cetuximab, emphasizing that it does not require stopping the medication.